Skip to contentA
Actinium Pharmaceuticals, Inc.
A
ATNMActinium Pharmaceuticals, Inc. Q1 2025 · 10-Q
Revenue—
Net Income-$15.94M-$15.94MN/M vs Q1 2024 EPS Diluted-$0.51-$0.51N/M vs Q1 2024 Operating Income-$16,638,000N/M Operating Cash Flow-$7,574,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Actinium Pharmaceuticals, Inc. · CIK 1388320 · Engraved from SEC EDGAR
ended Mar 31, 2025 · filed May 9, 2025 · 39 d after period end